Table 2.
Serious maternal adverse events associated with tocolytic treatment
Serious adverse event | Tocolytic | No of fetuses | Intensive care | Causality |
---|---|---|---|---|
Dyspnoea | Ritodrine | 1 | No | Probable |
Dyspnoea | Fenoterol | 1 | No | Probable |
Dyspnoea | Atosiban, nifedipine, and ritodrine* | 1 | No | Probable |
Dyspnoea | Fenoterol | 1 | No | Probable |
Dyspnoea | Nifedipine | 2 | No | Possible |
Dyspnoea | Atosiban and fenoterol* | 1 | Yes | Possible |
Hypotension | Nifedipine | 1 | No | Probable |
Hypotension | Nifedipine | 1 | No | Certain |
Hypotension | Nifedipine | 2 | No | Certain |
Hypotension | Nifedipine | 1 | No | Certain |
Cardiac failure | Atosiban then fenoterol† | 1 | Yes | Possible |
Hypoxia | Nifedipine and ritodrine* | 2 | No | Probable |
Lung oedema | Atosiban, nifedipine, and fenoterol* | 2 | Yes | Possible |
Lung oedema | Atosiban and nifedipine* | 1 | Yes | Probable |
Dyspnoea | Fenoterol | 1 | No | Unlikely |
Deep vein thrombosis | Ritodrine then nifedipine† | 2 | No | Unlikely |
*Combined courses: event occurred after simultaneous administration of all indicated tocolytics.
†Sequential courses: event occurred after administration of second tocolytic.